Form 4 for DGX Quest Diagnostics
Accepted 2022-03-09 00:00:00 ET · period of report 2022-03-07 · accession 0001022079-22-000052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-09 | 2022-03-07 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | A - Grant | $130.09 | +19.9K | 77.1K | +35% | +$2.58M | |
| 2022-03-09 | 2022-03-07 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | F - Tax | $130.09 | -10.3K | 66.8K | -13% | -$1.34M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-07 | A | A | 19,856 | $130.09 | 77,138 | D | — | — | (F1) Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). |
| 2 | Common | Common Stock | 2022-03-07 | F | D | 10,330 | $130.09 | 66,808 | D | — | — | (F2) Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |